Bavarian Nordic valuation upgraded thanks to deals
Danish biotech company Bavarian Nordic (Nasdaq: BAVA), which focuses on vaccines and novel cancer immunotherapies, has greatly benefited from deals with US pharma major Bristol-Myers Squibb (NYSE: BMY) and Johnson & Johnson (NYSE: JNJ).
In March, the company signed a deal with Bristol-Myers Squibb which has paid $60 million for an option to license exclusive rights to prostate cancer vaccine Prostvac and could pay a further $915 million in milestones.
In addition, Bavarian Nordic signed a $187 million deal with J&J for MVA-BN Filovirus for Ebola (both Zaire and Sudan strains) and Marburg viruses included a $43 million equity investment, in addition to an exclusive licensing and supply agreement. Bavarian Nordic has received a $25 million upfront payment and is eligible for a further $20 million of development and regulatory milestones in addition to undisclosed royalties on ex-Africa sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze